Explore the latest news from Khondrion and its team.
Enabling continued treatment in 52-week multi-centre study for patients who have completed ongoing KHENERGYZE Phase IIb study investigating...
NIJMEGEN, the Netherlands – 14 October 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
NIJMEGEN, the Netherlands – 26 August 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces the...
Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces its...
Study will examine the pharmacokinetics, safety and efficacy of sonlicromanol, one of the most advanced disease-modifying drug candidates in...
Primary Mitochondrial Diseases (PMDs) are a group of conditions that usually affect multiple organs and systems in the body. They are caused by problems in the mitochondria—the parts of our cells that produce energy...
Jan Smeitink: Serving the Mitochondrial Medicine Mission Embarking on the journey of biopharmaceutical innovation demands more than just...
Khondrion to participate in the 16th Annual Dutch Inborn Error Meeting and the United Mitochondrial Disease Foundation (UMDF) Bench to Bedside...
2022 – A Year in Review As 2022 draws to a close, Khondrion’s CEO Jan Smeitink reflects on the significant progress achieved by Khondrion in its...
How did you first become involved with the mitochondrial disease community and MitoCanada? I joined MitoCanada at a very exciting time, two months...
How did you first become involved with the mitochondrial disease community and what led you to the Mito Foundation? I first learnt of mitochondrial...
